Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Irinotecan Discontinuation and Reintroduction for Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2008-11-25
- Lead Sponsor
- Gachon University Gil Medical Center
- Target Recruit Count
- 72
- Registration Number
- NCT00320320
- Locations
- 🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of
Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC
- Conditions
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2008-03-12
- Lead Sponsor
- Gachon University Gil Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT00319800
- Locations
- 🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of
Cisplatin, Irinotecan, and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2018-05-08
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 82
- Registration Number
- NCT00316862
- Locations
- 🇺🇸
Mountainview Medical, Berlin, Vermont, United States
🇺🇸Memorial Hospital of South Bend, South Bend, Indiana, United States
🇺🇸Michiana Hematology-Oncology, PC - South Bend, South Bend, Indiana, United States
Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon
- Conditions
- Interventions
- First Posted Date
- 2006-04-13
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 7
- Registration Number
- NCT00314353
- Locations
- 🇺🇸
NSABP Operations Center, Pittsburgh, Pennsylvania, United States
Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2014-09-30
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 59
- Registration Number
- NCT00311584
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States
Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2006-03-29
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 55
- Registration Number
- NCT00308529
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
Combination Chemotherapy as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2016-05-30
- Lead Sponsor
- Federation Francophone de Cancerologie Digestive
- Target Recruit Count
- 282
- Registration Number
- NCT00303771
- Locations
- 🇫🇷
Clinique De Rochebelle, Ales, France
🇫🇷Centre hospitalier d'Alencon, Alencon, France
🇫🇷Centre Hospitalier d'Abbeville, Abbeville, France
Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 9
- Registration Number
- NCT00303992
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
- Conditions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2008-07-24
- Lead Sponsor
- Federation Francophone de Cancerologie Digestive
- Target Recruit Count
- 78
- Registration Number
- NCT00303745
- Locations
- 🇫🇷
Centre Hospitalier, Chalon Sur Saone, France
🇫🇷Centre Hospitalier Universitaire Ambroise Pare - Boulogne, Boulogne, France
🇫🇷Clinique Pasteur, Guilherand Granges, France
Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors
- First Posted Date
- 2006-03-03
- Last Posted Date
- 2012-08-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 59
- Registration Number
- NCT00298675
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.